RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Financial documents

Analysts and consensus

Analyst Coverage

SEBChristopher Uhdechristopher.uhde@seb.se+46 876 385 53Stockholm
RBCZoe KaramanoliZoe.Karamanoli@rbccm.com+44 7834 765119London
ABG Sundal CollierGonzalo Artiach CastañónGonzalo.Artiach@abgsc.se+46 73 321 73 96  Stockholm
RedeyeJohan Unnerusjohan.unnerus@redeye.se+46 724 023 385Stockholm
Van Lanschot KempenSuzanne van Voorthuizen


+31 6 29 71 3490

CarnegieErik Hultgårderik.hultgard@carnegie.se+46 (0)8 5886 9237Stockholm
Intron Health ResearchNaresh ChouhanNaresh@IntronHealthResearch.com+44 7939 224 322London
Ökonomisk UgebrevLars Hatholthatholt@outlook.com+45 22 23 78 15Copenhagen
Erik Penser BankLudvig Svenssonludvig.svensson@penser.se+46 (0) 84 638 059Stockholm
H.C. Wainwright & Co.Douglas Tsaodtsao@hcwresearch.com+1 212 916 3968New York City
Bryan, Garnier & Co.Ingrid Gafanhaoigafanhao@bryangarnier.comParis

Analyst Consensus

   Patient uptake, EURevenue estimates, SEKmEBIT, SEKmOperating Cash Flow, SEKmCash position, SEKm
Consensus modelPrice target, SEKWACCQ4'22eFY'22eFY'23eFY'24eFY'25eQ4'22eFY'22eFY'23eFY'24eFY'25eQ4'22eFY'22eFY'23eFY'24eFY'25eQ4'22eFY'22eFY'23eFY'24eFY'25eQ4'22eFY'22eFY'23eFY'24eFY'25e
Average19911,2%7275310118030147210399844-178-609-642-547-374-170-588-655-508-3931 4551 4551 050784569
Median20011,5%8265210118833153206367862-175-610-666-490-435-170-586-643-492-4871 4421 442951754719
High 26515,0%83064136242351592475701 219-164-585-500-259-14-157-512-491-301231 5511 5511 5691 5361 040
Low1217,6%625467210620131181298552-198-641-737-848-747-183-641-950-647-5361 4001 400757193-249
Number of contributions12124777747777477772777777776
Hold 0
 Sell 0

This is a company-collected consensus prepared with consolidated estimates submitted from research analysts covering the Hansa Biopharma stock. The consensus provided is based on a collection of estimates done on a quarterly basis. Any opinions, forecasts, estimates, projections or predictions regarding Hansa Biopharma’s performance made by the analysts (and, therefore, the consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of Hansa Biopharma or its management. Hansa Biopharma does not by providing these estimates imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations made or provided by such analysts. Hansa Biopharma assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.